FDA Approval Alert: The Need-to-Know | Subcutaneous Daratumumab Combo in Newly Diagnosed Multiple Myeloma

In July 2024, the FDA approved daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide and dexamethasone as induction and consolidation therapy for patients with newly diagnosed multiple myeloma eligible to undergo ASCT.

Data from the PERSEUS trial support the FDA approval of the daratumumab-containing regimen in newly diagnosed multiple myeloma.
FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma
Article
Jul 30, 2024 10:51 PM
Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.